Amgen to acquire ChemoCentryx for $3.7bn
The nearly $4bn ChemoCentryx acquisition will expand Amgen’s inflammation and nephrology portfolio and pipeline.
List view / Grid view
The nearly $4bn ChemoCentryx acquisition will expand Amgen’s inflammation and nephrology portfolio and pipeline.
A study to demonstrate the safety and efficacy of avacopan has produced topline results, according to the pharmaceutical company developing the drug.
25 May 2016 | By Victoria White, Digital Content Producer
ChemoCentryx’s CCX168 has strong potential to address major unmet needs in the vasculitis space, according to an analyst with GlobalData...